Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 14Gastrointestinal 10Gynecologic 6Tumor-Agnostic 3Genitourinary 3Other solid neoplasm 2Sarcoma 1Other hematologic neoplasm 1NET 1Endocrine 1CNS 1Breast 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 296Cytarabine 261fludarabine phosphate 218Rituximab 195fludarabine 182Methotrexate 152Whole-Body Irradiation 140Mycophenolic Acid 124Azacitidine 122Tacrolimus 116Busulfan 110Filgrastim 104Granulocyte Colony-Stimulating Factor 98Etoposide 91Peripheral Blood Stem Cell Transplantation 90Dexamethasone 89Vincristine 88Melphalan 80Cyclosporine 74Lenalidomide 73Daunorubicin 70Decitabine 69Clofarabine 69Antilymphocyte Serum 67Calcium Dobesilate 61venetoclax 60Doxorubicin 58Imatinib Mesylate 57Alemtuzumab 56ibrutinib 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × nintedanib × Other hematologic neoplasm × Clear all
NCT02665143 2022-04-08

A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia

Yale University

Phase 2 Completed
25 enrolled 7 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡